SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Perez CA. Nasopharynx. In: PerezCA, BradyLW, editors. Principles and practice of radiation oncology, 2nd ed. Philadelphia: Lippincott Company, 1992: 617643.
  • 2
    Dimery IW, Peters LJ, Goepfert H, et al. Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma. J Clin Oncol. 1993; 11(10): 19191928.
  • 3
    Dimery IW, Legha SS, Peters LJ, Goepfert H, Oswald MJ. Adjuvant chemotherapy for advanced nasopharyngeal carcinoma. Cancer. 1987; 60(5): 943949.
  • 4
    Khoury GG, Paterson IC. Nasopharyngeal carcinoma: a review of cases treated by radiotherapy and chemotherapy. Clin Radiol. 1987; 38(1): 1720.
  • 5
    Chan AT, Teo PM, Leung TW, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma [see comments]. Int J Radiat Oncol Biol Phys. 1995; 33(3): 569577.
  • 6
    Chua DT, Sham JS, Choy D, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing CDDP and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group [see comments]. Cancer. 1998;83(11): 22702283.
  • 7
    International Nasopharynx Cancer Study Group VIT. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy VS. radiotherapy alone in stage IV (3N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys. 1996; 35(3): 463469.
  • 8
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) [editorial]. Int J Radiat Oncol Biol Phys. 1995; 31(5): 13411346.
  • 9
    Kaplan EL, Meier P. Non-parametric estimates from incomplete observations. J Am Stat Assoc. 1953; 53: 457480.
  • 10
    Bachouchi M, Cvitkovic E, Azli N, et al. High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy. J Natl Cancer Inst. 1990; 82(7): 616620.
  • 11
    Clark JR, Norris CM Jr., Dreyfuss AI, et al. Nasopharyngeal carcinoma: the Dana-Farber Cancer Institute experience with 24 patients treated with induction chemotherapy and radiotherapy. Ann Otol Rhinol Laryngol. 1987;96(5): 608614.
  • 12
    Lin JC, Jan JS, Hsu CY. Neoadjuvant chemotherapy for advanced nasopharyngeal carcinoma. Am J Clin Oncol. 1995; 18(2): 139143.
  • 13
    Tannock I, Payne D, Cummings B, Hewitt K, Panzarella T. Sequential chemotherapy and radiation for nasopharyngeal cancer: absence of long-term benefit despite a high rate of tumor response to chemotherapy. J Clin Oncol. 1987; 5(4): 629634.
  • 14
    Olmi P, Cellai E, Chivacci E, et al. Computed tomography in nasopharyngeal carcinoma. Part I: T-stage conversion with CT-staging. Int J Radiat Oncol Biol Phys. 1990;19(5): 11711175.
  • 15
    Andersson-Anvret M, Forsby N, Klein G, Henle W. Relationship between the Epstein–Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination. Int J Cancer. 1977; 20(4): 486494.
  • 16
    Hoppe RT, Williams J, Warnke R, Goffinet DR, Bagshaw MA. Carcinoma of the nasopharynx—the significance of histology. Int J Radiat Oncol Biol Phys. 1978; 4( 3–4): 199205.
  • 17
    Lombardi F, Gasparini M, Gianni C, De Marie M, Molinari R, Pilotti S. Nasopharyngeal carcinoma in childhood. Med Pediatr Oncol. 1982; 10(3): 243250.
  • 18
    Mesic JB, Fletcher GH, Goepfert H. Megavoltage irradiation of epithelial tumors of the nasopharynx. Int J Radiat Oncol Biol Phys. 1981; 7(4): 447453.
  • 19
    Rosenthal DI, Pistenmaa DA, Glatstein E. A review of neoadjuvant chemotherapy for head and neck cancer: partially shrunken tumors may be both leaner and meaner. Int J Radiat Oncol Biol Phys. 1994; 28(1): 315320.
  • 20
    Withers HR, Taylor JMF, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988; 27: 131146.
  • 21
    Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996; 14(5): 16721678.
  • 22
    Forastiere AA, Shank D, Neuberg D, Taylor SG, DeConti RC, Adams G. Final report of a Phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer. 1998; 82(11): 22702274.
  • 23
    Bissery MC, Vrignaud P, Lavelle F. Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination. Semin Oncol. 1995; 22(6 Suppl 13 ): 316.
  • 24
    Posner MR, Glisson B, Frenette G, et al. Multicenter Phase I–II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001; 19(4): 10961104.
  • 25
    Colevas AD, Norris CM, Tishler RB, et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol. 1999; 17(11): 35033511.
  • 26
    Lin JC, Chen KY, Jan JS, Hsu CY. Partially hyperfractionated accelerated radiotherapy and concurrent chemotherapy for advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1996; 36(5): 11271136.
  • 27
    Al-Sarraf M, Pajak TF, Cooper JS, Mohiuddin M, Herskovic A, Ager PJ. Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a radiation therapy oncology group study. J Clin Oncol. 1990; 8(8): 13421351.
  • 28
    Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol. 1998; 16(4): 1310-1317.